Immunomodulation During Pregnancy

Launched by CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA, E.P.E. · Mar 15, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Immunomodulation During Pregnancy," is studying the effects of low-dose aspirin on the immune system of pregnant women. Specifically, researchers want to understand how aspirin influences certain immune cells that play a role in pregnancy complications, particularly in women at high risk for a condition called preeclampsia, which can cause high blood pressure and other serious issues during pregnancy.

To be eligible for this study, participants must be pregnant with a single baby and have their first prenatal visit before 14 weeks of pregnancy. They should also be considered at high risk for preeclampsia based on specific medical criteria. Women with multiple pregnancies, autoimmune diseases, or a history of miscarriages are excluded from the trial. Participants will complete online surveys about their health and any joint pain they experience over a period of five years. This study aims to gather important information that could help improve care for pregnant women in the future.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria: - Singleton pregnancy
• • Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation
• • Gestational age determined by first-trimester ultrasound
• • Study group: Women classified as high risk for PE according to clinical/historical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve.
• • Exclusion Criteria: Multiple pregnancy
• • Autoimmune diseases
• • Prior use of LDA or other immunomodulatory medication before potential recruitment
• • History of spontaneous miscarriages and/or medical termination of pregnancy
• • Fetal malformation